RAGE receptor targeted bioconjuguate lipid nanoparticles of diallyl disulfide for improved apoptotic activity in triple negative breast cancer: <i>in vitro</i> studies

Siddhartha, Venkata Talluri; Pindiprolu, Sai Kiran S. S.; Chintamaneni, Pavan Kumar; Tummala, Shashank; Kumar, Surendra

doi:10.1080/21691401.2017.1313267

Cited by 51 publications

(41 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They can passively accumulate at the tumour site owing to the leaky vasculature of tumour [25]. In addition, active targeting by surface modification of suitable ligands for tumour biomarkers improves the site specificity of nanocarriers [26][27][28]. Therefore, nanocarriers are being widely employed in recent years for tumour targeted drug delivery.…”

Section: Targeting Bcscs Using Nanocarriersmentioning

confidence: 99%

Nanocarrier based approaches for targeting breast cancer stem cells

Pindiprolu

Chintamaneni

Karri

2017

Artificial Cells, Nanomedicine, and Biotechnology

Self Cite

View full text Add to dashboard Cite

Breast cancer stem cells (BCSCs) are heterogeneous subpopulation of tumour initiating cells within breast tumours. They are spared even after chemotherapy and responsible for tumour relapse. Targeting BCSCs is, therefore, necessary to achieve radical cure in breast cancer. Despite the availability of agents targeting BCSCs, their clinical application is limited due to their off-target effects and bioavailability issues. Nanotechnology based drug carriers (nanocarriers) offer various advantages to deliver anti-BCSCs agents specifically to their target sites by overcoming their bioavailability issues. In this review, we describe various strategies for targeting BCSCs using nanocarriers.

show abstract

Section: Targeting Bcscs Using Nanocarriersmentioning

confidence: 99%

Nanocarrier based approaches for targeting breast cancer stem cells

Pindiprolu

Chintamaneni

Karri

2017

Artificial Cells, Nanomedicine, and Biotechnology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Among them, APAF1 plays a key role in the mechanism of apoptosis and can activate the caspase cascade reaction responsible for the apoptotic effector phase [70]. In addition, IL-10 in serum induces apoptosis of T cells by activating the caspase-8 pathway by Fas signaling [71]. New research confirms that receptor for advanced glycation endproduct (RAGE) can specifically deliver DADS into three negative breast cancer cells and significantly enhance the cytotoxicity of DADS by reducing anti-apoptotic proteins and upregulation of pro-apoptotic protein [72].…”

Section: Activation Of the Apoptotic Pathways By Dadsmentioning

confidence: 99%

The Progress of Diallyl Disulfide in Anti-Cancer

Lz¹,

Liao²,

Wang³

et al. 2017

Chemotherapy

View full text Add to dashboard Cite

Considerable evidence in recent years suggests that garlic has anti-proliferative effects on various types of cancer. Garlic contains water-soluble and oil-soluble sulfur compounds. Oil-soluble compounds (OSCs), such as diallyl sulfide (DAS), diallyl disulfide (DADS), diallyl trisulfide (DATS) and ajoene are more effective than watersoluble compounds in protection against cancer. DADS, a major organosulfur compound derived from garlic, can reduce carcinogen-induced cancers in experimental animals and inhibit the proliferation of various types of cancer cells. The mechanisms of these action of DADS include activation of metabolic enzymes that detoxify carcinogens, suppression of the formation of DNA adducts, antioxidant effects, regulation of cell-cycle progression, induction of apoptosis, and inhibition of angiogenesis and metastasis. These topics are discussed in depth in this review.

show abstract

“…One study showed that a SLN formulation of docetaxel functionalized with angiopep-2 can specifically bind to the LDL-receptor-related protein 1 (LRP1), which is overexpressed at the BBB, showing higher in vitro cytotoxicity and BBB permeability by receptor mediated endocytic processes [ 112 ]. Other studies are based on how to attaching a targeting ligand to an SLN, such as by linking a fatty acid of the NP to an amino group of the ligand [ 113 ], an amino group of a phospholipid to an acid group of the ligand [ 114 ], or an amino group of the chitosan coating to an acid group of the ligand [ 115 ]. These could lead to better brain drug delivery by the SLNs across BBB.…”

Section: Methods To Improve Slns For Brain Drug Deliverymentioning

confidence: 99%

Solid Lipid Nanoparticles (SLNs): An Advanced Drug Delivery System Targeting Brain through BBB

et al. 2021

View full text Add to dashboard Cite

The blood–brain barrier (BBB) plays a vital role in the protection and maintenance of homeostasis in the brain. In this way, it is an interesting target as an interface for various types of drug delivery, specifically in the context of the treatment of several neuropathological conditions where the therapeutic agents cannot cross the BBB. Drug toxicity and on-target specificity are among some of the limitations associated with current neurotherapeutics. In recent years, advances in nanodrug delivery have enabled the carrier system containing the active therapeutic drug to target the signaling pathways and pathophysiology that are closely linked to central nervous system (CNS) disorders such as Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), multiple sclerosis (MS), brain tumor, epilepsy, ischemic stroke, and neurodegeneration. At present, among the nano formulations, solid lipid nanoparticles (SLNs) have emerged as a putative drug carrier system that can deliver the active therapeutics (drug-loaded SLNs) across the BBB at the target site of the brain, offering a novel approach with controlled drug delivery, longer circulation time, target specificity, and higher efficacy, and more importantly, reducing toxicity in a biomimetic way. This paper highlights the synthesis and application of SLNs as a novel nontoxic formulation strategy to carry CNS drugs across the BBB to improve the use of therapeutics agents in treating major neurological disorders in future clinics.

show abstract

RAGE receptor targeted bioconjuguate lipid nanoparticles of diallyl disulfide for improved apoptotic activity in triple negative breast cancer: in vitro studies

Cited by 51 publications

References 31 publications

Nanocarrier based approaches for targeting breast cancer stem cells

Nanocarrier based approaches for targeting breast cancer stem cells

The Progress of Diallyl Disulfide in Anti-Cancer

Solid Lipid Nanoparticles (SLNs): An Advanced Drug Delivery System Targeting Brain through BBB

Contact Info

Product

Resources

About